Lyon Street Capital’s Trinity Biotech TRIB Stock Holding History

Lyon Street Capital’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-28,189	Closed	-$1.61M	–	41
2015 Q3	$1.61M	Sell	28,189 -6,503	-19%	-$523K	1.17%	27
2015 Q2	$3.13M	Sell	34,692 -79,385	-70%	-$6.87M	2.25%	16
2015 Q1	$11M	Sell	114,077 -60,374	-35%	-$5.58M	4.73%	2
2014 Q4	$15.3M	Buy	174,451 +26,517	+18%	+$2.29M	6.34%	2
2014 Q3	$13.5M	Buy	147,934 +20,076	+16%	+$2.17M	6.33%	2
2014 Q2	$14.7M	Buy	127,858 +15,850	+14%	+$1.88M	6.49%	3
2014 Q1	$13.6M	Buy	112,008 +22,195	+25%	+$2.91M	6.28%	3
2013 Q4	$11.3M	Buy	89,813 +8,296	+10%	+$996K	5.08%	7
2013 Q3	$8.87M	Buy	81,517 +7,745	+10%	+$755K	4.37%	7
2013 Q2	$6.22M	Buy	+73,772	New	+$6.12M	3.08%	9

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Lyon Street Capital's TRIB Position: Q4 2015 in Review

Lyon Street Capital sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 28,189 shares — an estimated $1.61M sold.

Lyon Street Capital first reported a position in TRIB in Q2 2013 and held it in 10 quarters. The position peaked at $15.3M in Q4 2014. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

Lyon Street Capital reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
Lyon Street Capital sold 28,189 Trinity Biotech shares in Q4 2015, an estimated $1.61M.
Lyon Street Capital first reported a position in Trinity Biotech in Q2 2013 and held it in 10 quarters.
Lyon Street Capital's Trinity Biotech position peaked at $15.3M in Q4 2014.
82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Lyon Street Capital's 13F filing for Q4 2015, filed 16 Feb 2016.